MedPath

Dacarbazine

Dacarbazine for Injection, USP

Approved
Approval ID

b6b97e41-5f15-498c-abfb-d8443ea4d216

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 20, 2022

Manufacturers
FDA

Fresenius Kabi USA, LLC

DUNS: 608775388

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

DACARBAZINE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63323-128
Application NumberANDA075371
Product Classification
M
Marketing Category
C73584
G
Generic Name
DACARBAZINE
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateOctober 20, 2022
FDA Product Classification

INGREDIENTS (3)

CITRIC ACID MONOHYDRATEInactive
Quantity: 10 mg in 1 mL
Code: 2968PHW8QP
Classification: IACT
DACARBAZINEActive
Quantity: 10 mg in 1 mL
Code: 7GR28W0FJI
Classification: ACTIB
MANNITOLInactive
Quantity: 3.75 mg in 1 mL
Code: 3OWL53L36A
Classification: IACT

DACARBAZINE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63323-127
Application NumberANDA075371
Product Classification
M
Marketing Category
C73584
G
Generic Name
DACARBAZINE
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateOctober 20, 2022
FDA Product Classification

INGREDIENTS (3)

CITRIC ACID MONOHYDRATEInactive
Quantity: 10 mg in 1 mL
Code: 2968PHW8QP
Classification: IACT
MANNITOLInactive
Quantity: 5 mg in 1 mL
Code: 3OWL53L36A
Classification: IACT
DACARBAZINEActive
Quantity: 10 mg in 1 mL
Code: 7GR28W0FJI
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Dacarbazine - FDA Drug Approval Details